US Stock MarketDetailed Quotes

JNJ Johnson & Johnson

Watchlist

144.020
-0.600-0.41%

Close Jan 2 16:00 ET

144.260
+0.240+0.17%

Post 17:50 ET

346.75BMarket Cap23.42P/E (TTM)

Johnson & Johnson Stock Forum

Stock_Drift

7 hours ago

J&J announces dividend for Q1 2025

$Johnson & Johnson (JNJ.US)$

ひな☆彡 SOXL(Bull)

Dec 25, 2024 03:01

Merry Christmas 🎄 Thank U ☺️ & Stocks that I think will grow 2025…!!

Thank you so much for your support. I want to say thank you again, as I just reached 1500 followers.
If you haven’t got the Christmas frame, go and get it. This is perfect for my current avatar picture and I am very happy… so cute :)
Next weekly report would be likely next year, and this will be my 2024 Annual Report, with all transparent sharing :)
You might be wondering why I would do that because I have literally no financial...

Christmas is Coming: Share Your Holiday Snippets

ひな☆彡 SOXL(Bull)

Dec 23, 2024 20:41

Weekly Report W3 December 🎄

Hi, all please find the attached report;
I hope you have a good Christmas holiday and happy new year soon….
I did spend some money on shopping etc and bit broke right now ahahaha
Cheers,

Share Your Profit/Loss

Phil Dunn

Dec 21, 2024 11:00

Review of the very harsh 3rd week Dec

Devastating Crash of $Novo-Nordisk A/S (NVO.US)$ and Strong Rebound of $NVIDIA (NVDA.US)$ on Black Friday.
I made a difficult but crucial decision on Friday to sell off losing positions at pre-market which were moving downtrend so badly like $Novo-Nordisk A/S (NVO.US)$ , $D.R. Horton (DHI.US)$ , $Huntington Ingalls Industries (HII.US)$ , $MarketAxess (MKTX.US)$ . Especially obesity drug giant NVO which collapsed 25% at pre-market after disappointing trial results o...

Powell says no hurry for Fed rate cuts, how will you adjust your investment strategy?

Ultratech

Dec 20, 2024 20:01

$Johnson & Johnson (JNJ.US)$
bottoming soon

KyleyW

Dec 16, 2024 12:06

$Johnson & Johnson (JNJ.US)$ how low can it drop? below 140? i wanted to enter

10xStockPicks

Dec 15, 2024 18:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

10xStockPicks

Dec 15, 2024 15:56

Buying This Takeover Target Offers 10X Upside. Esperion Therapeutics.

$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...

10xStockPicks

Dec 14, 2024 21:19

This $2.25 Stock Soon To Turn A Profit Is Highly Likely To Be Acquired Above $10

This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...